How Acyclovir Stacks Up Against Other Antivirals
Acyclovir treats herpes simplex virus (HSV-1, HSV-2), varicella-zoster virus (VZV, causing shingles and chickenpox), and sometimes other herpesviruses. It works by inhibiting viral DNA polymerase after activation by viral thymidine kinase, limiting viral replication.[1] Newer antivirals often target similar viruses but differ in bioavailability, dosing convenience, and resistance profiles.
Acyclovir vs. Valacyclovir and Famciclovir
Valacyclovir (Valtrex) is an oral prodrug of acyclovir with 54% bioavailability versus acyclovir's 15-30%, allowing less frequent dosing—once or twice daily instead of 3-5 times.[2] Famciclovir (Famvir), a penciclovir prodrug, treats the same viruses with similar efficacy but better pharmacokinetics for shingles, reducing pain duration by about one day in trials.[3] All three have comparable cure rates for initial herpes outbreaks (around 80-90% lesion healing in 7-10 days), but valacyclovir and famciclovir cut transmission risk more due to steady blood levels.[1][2]
| Drug | Bioavailability | Typical Dosing for Herpes | Shingles Treatment Duration |
|------|-----------------|---------------------------|-----------------------------|
| Acyclovir | 15-30% | 200mg 5x/day | 7-10 days |
| Valacyclovir | 54% | 1g 2x/day | 7 days |
| Famciclovir | 77% | 250mg 3x/day | 7 days |
Acyclovir costs less generically ($10-20 for a course) compared to $40-60 for valacyclovir.[4]
How It Compares to Ganciclovir and Valganciclovir for CMV
Cytomegalovirus (CMV) requires ganciclovir or its prodrug valganciclovir, which are more potent against CMV due to higher affinity for CMV's UL97 kinase and DNA polymerase. Acyclovir has minimal CMV activity.[1] Ganciclovir treats CMV retinitis in immunocompromised patients, with 80-90% response rates versus acyclovir's ineffectiveness there.[5] Valganciclovir offers oral convenience over IV ganciclovir, but both carry higher myelosuppression risk (neutropenia in 20-40%).[5]
Acyclovir vs. Oseltamivir for Flu and Remdesivir for COVID
Oseltamivir (Tamiflu) targets influenza neuraminidase, shortening symptoms by 1 day if started within 48 hours—acyclovir has no flu activity.[6] Remdesivir (Veklury), an RNA polymerase inhibitor, cuts COVID-19 recovery time by 5 days in hospitalized patients but isn't for herpes.[7] Acyclovir stays niche for herpesviruses; crossover use fails due to different viral mechanisms.
Resistance and When Newer Drugs Win Out
HSV resistance to acyclovir occurs in 5% of immunocompetent patients and 30% of AIDS patients with frequent exposure, often from thymidine kinase mutations.[1] Foscarnet or cidofovir then step in as backups, bypassing resistance but with kidney toxicity (up to 30% nephrotoxicity).[8] Valacyclovir shows similar resistance rates but lower overall due to better adherence.
Side Effects and Patient Tradeoffs
All nucleoside analogs like acyclovir cause nausea (10-20%), headache, and rare neurotoxicity. Acyclovir risks more renal issues with IV use (crystalluria in 5-12% if dehydrated).[1] Newer options like valacyclovir reduce this via better solubility. For outbreaks, patients pick acyclovir for cost; for suppression, valacyclovir for convenience.
[1] CDC - Herpes Treatment Guidelines
[2] NEJM - Valacyclovir vs Acyclovir
[3] Cochrane - Antivirals for Shingles
[4] Drugs.com - Price Comparison
[5] NIH - CMV Treatment
[6] FDA - Tamiflu Label
[7] NEJM - Remdesivir for COVID-19
[8] IDSA - HSV Resistance Guidelines